Review Product Marketing Authorisation For Human Use «Ultravist».

Original Language Title: Modifica dell'autorizzazione all'immissione in commercio delmedicinale per uso umano «Ultravist».

Read the untranslated law here: http://www.gazzettaufficiale.it/atto/serie_generale/caricaArticoloDefault/originario?atto.dataPubblicazioneGazzetta=2015-03-19&atto.codiceRedazionale=15A01908&elenco30giorni=false&atto.tipoProvvedimento=DECRETO

Retrieved February 23, 2015 V&A # 330 of authorization determines variation: C.I. 4) one or more amendments to the summary of product characteristics, labelling and package leaflet after new data on quality, preclinical, clinical or pharmacovigilance medicine ULTRAVIST;
Authorized updating of the summary of product characteristics to sections 4.4 and 4.5 and corresponding paragraphs leaflet and labels, relative to medicine ULTRAVIST, shapes and packages listed below: AIC # 026965018-"240 mg/ml solution for injection 50 ml 1 bottle" AIC # 026965044-"300 mg/ml solution for injection 50 ml 1 bottle" AIC # 026965057-"300 mg/ml injection 026965069 75 ml bottle # 1" AIC-"300 mg/ml solution for injection 100 ml 1 bottle"
AIC # 026965083-"370 mg/ml solution for injection 50 ml 1 bottle" AIC # 026965095-"370 mg/ml solution for injection 100 ml 1 vial" AIC # 026965107-"370 mg/ml injection 026965121 200 ml bottle # 1" AIC-"150 mg/ml injection 026965133 200 ml bottle # 1" AIC-"300 mg/ml injection 026965145 200 ml bottle # 1" AIC-"300 mg/ml solution for injection 500 ml 1 vial" AIC # 026965160-"370 mg/ml solution for injection" 1 bottle 500 ml AIC # 026965184-"300 mg/ml solution for injection" 1 vial 20 ml AIC # 026965196-"300 mg/ml solution for infusion" AIC 75 ml cartridge n. 026965208-"300 mg/ml solution for infusion" AIC 100 ml cartridge n. 026965210-"300 mg/ml solution for infusion" AIC 125 ml cartridge n. 026965222-"300 mg/ml solution for infusion" AIC 150 ml cartridge n. 026965234-"370 mg/ml solution for infusion" AIC 75 ml cartridge n. 026965246-"370 mg/ml solution for infusion" AIC 100 ml cartridge n. 026965259-"370 mg/ml solution for infusion" AIC 125 ml cartridge n. 026965261-"370 mg/ml solution for infusion" 150 ml cartridge handouts corrected and approved shall be annexed to the assessment, referred to in this excerpt.
MAh: BAYER PHARMA AG with registered office and address in MULLERSTRASSE, 178, 13342-Berlin (Germany) printed 1. The marketing authorisation holder should make the changes, after the date of entry into force of this determination, the summary of product characteristics; no later than six months from the same date the package leaflet and labelling.
2. In accordance with art. 80, paragraphs 1 and 3, of Legislative Decree No 219 April 24, 2006 and s, leaflet and labels must be written in Italian and, limited to medicinal products marketed in the province of Bolzano, in German. The mAh avails itself of the complementary use of foreign languages, must give prior notice to the AIFA and keep available the certified translation of German texts and/or in another foreign language. In case of non-compliance with the provisions on the labelling and package leaflet shall apply sanctions under art. 82 of the aforementioned legislative decree.
Inventory disposal Both lots already products on the date of entry into force of this determination that the batches produced during the period referred to in article 2, paragraph 1, of the present, not bearing approved changes can be kept on the market until the expiration date printed on the label of the medicine. Pharmacists are required to deliver the package leaflet updated users, as from the end of 30 days from the date of publication in the Official Gazette of the Italian Republic of this determination. The Mah makes accessible to pharmacist leaflet updated within the same timeframe.
Date of determination: from the day following that of its publication, to decompress, in Gazzetta Ufficiale della Repubblica Italiana.